MX2022012592A - Construcciones de citocinas activables y composiciones y metodos relacionados. - Google Patents
Construcciones de citocinas activables y composiciones y metodos relacionados.Info
- Publication number
- MX2022012592A MX2022012592A MX2022012592A MX2022012592A MX2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A
- Authority
- MX
- Mexico
- Prior art keywords
- activatable
- methods
- related compositions
- cytokine
- constructs
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 4
- 108090000695 Cytokines Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 238000006471 dimerization reaction Methods 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008542P | 2020-04-10 | 2020-04-10 | |
| US202163161889P | 2021-03-16 | 2021-03-16 | |
| US202163164849P | 2021-03-23 | 2021-03-23 | |
| PCT/US2021/026675 WO2021207669A1 (en) | 2020-04-10 | 2021-04-09 | Activatable cytokine constructs and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012592A true MX2022012592A (es) | 2022-12-07 |
Family
ID=75747127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012592A MX2022012592A (es) | 2020-04-10 | 2021-04-09 | Construcciones de citocinas activables y composiciones y metodos relacionados. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11365233B2 (https=) |
| EP (1) | EP4133085A1 (https=) |
| JP (1) | JP2023520922A (https=) |
| KR (1) | KR20220167295A (https=) |
| CN (1) | CN115667523B (https=) |
| AU (2) | AU2021254283B2 (https=) |
| BR (1) | BR112022020440A2 (https=) |
| CA (1) | CA3174786A1 (https=) |
| IL (1) | IL297225A (https=) |
| MX (1) | MX2022012592A (https=) |
| WO (1) | WO2021207669A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| US20240384323A1 (en) | 2021-08-30 | 2024-11-21 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| AU2022361492A1 (en) * | 2021-10-08 | 2024-05-02 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| CA3245158A1 (en) * | 2022-03-03 | 2023-09-07 | The Trustees Of The University Of Pennsylvania | Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidism |
| WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| US20250333487A1 (en) | 2022-03-25 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
| WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| US20240067691A1 (en) * | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| DE60129695T2 (de) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| ATE513563T1 (de) | 2000-10-09 | 2011-07-15 | Isis Innovation | Therapeutische und toleranz-induzierende antikörper |
| US6942853B2 (en) | 2001-01-09 | 2005-09-13 | Queen Mary And Westfield College | Latent fusion protein |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| MX2007014889A (es) * | 2005-05-26 | 2008-02-19 | Schering Corp | Fusion de interferon-inmunoglobulina g. |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| CA2697032C (en) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
| WO2009079837A1 (en) | 2007-12-18 | 2009-07-02 | Hangzhou Jiuyuan Gene Engineering Co., Ltd. | A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| EP2553101A4 (en) | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| HRP20150664T1 (hr) | 2010-12-03 | 2015-07-31 | Adamed Sp. Z O.O. | Antikancerogeni fuzijski protein |
| HRP20200470T1 (hr) | 2011-01-18 | 2020-10-02 | Bioniz, Llc | Pripravci za modulaciju aktivnosti gama-c-citokina |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP2854845B1 (en) * | 2012-06-01 | 2018-03-28 | IBC Pharmaceuticals, Inc. | Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| IL270562B (en) * | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| GB201411506D0 (en) * | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| RS59340B1 (sr) | 2014-11-06 | 2019-10-31 | Hoffmann La Roche | Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP2019518786A (ja) | 2016-05-06 | 2019-07-04 | 牧林 王 | インターロイキンの組み合せ及びその使用 |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| CN111050803A (zh) | 2017-06-20 | 2020-04-21 | 德克萨斯大学系统董事会 | 用于治疗癌症的干扰素前药 |
| CA3287794A1 (en) | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| CA3081539A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| WO2020113403A1 (en) | 2018-12-04 | 2020-06-11 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2019173832A2 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| US12030721B2 (en) | 2018-06-21 | 2024-07-09 | Tgw Logistics Group Gmbh | Storage and order picking system and method for picking ordered articles from a hanging bag and another load aid |
| EP3810624A4 (en) | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN112867503A (zh) | 2018-08-24 | 2021-05-28 | 希望之城 | 掩蔽的细胞因子缀合物 |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| JP2022502443A (ja) | 2018-09-28 | 2022-01-11 | ピエール、ファーブル、メディカマン | 癌の処置のための新規な免疫サイトカイン |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| AU2019395266A1 (en) | 2018-12-14 | 2021-06-17 | Proviva Therapeutics (Hong Kong) Limited | IL-15 compositions and methods of use thereof |
| WO2020214690A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| JP2022533254A (ja) | 2019-05-24 | 2022-07-21 | プロヴィヴァ セラピューティクス （ホン コン） リミテッド | Ｉｌ－２組成物およびその使用方法 |
| CN114127277A (zh) | 2019-06-05 | 2022-03-01 | 中外制药株式会社 | 蛋白酶底物和包含蛋白酶切割序列的多肽 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| CA3146156A1 (en) | 2019-07-12 | 2021-01-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
| MX2022000991A (es) | 2019-07-25 | 2022-05-24 | Univ Chicago | Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa. |
| EP4004026A4 (en) | 2019-07-25 | 2023-11-15 | Trutino Biosciences Inc. | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER |
| CA3148505A1 (en) | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Novel il-2 fusion molecules |
| US20220289822A1 (en) | 2019-08-21 | 2022-09-15 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220356221A1 (en) | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| CN115315434A (zh) | 2019-12-05 | 2022-11-08 | 免疫靶向有限公司 | 白细胞介素15融合蛋白和前药及其组合物和方法 |
| MX2022007202A (es) | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| US20240043489A1 (en) | 2020-01-15 | 2024-02-08 | Trutino Biosciences Inc. | Cytokine Prodrugs Comprising a Cleavable Linker |
| JP7773991B2 (ja) | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
| WO2021202354A1 (en) | 2020-03-30 | 2021-10-07 | Proviva Therapeutics (Hong Kong) Limited | Il-2/il-15 compositions and methods of use thereof |
| AU2021248919A1 (en) | 2020-04-01 | 2022-10-13 | Xilio Development, Inc. | Masked IL-12 cytokines and their cleavage products |
| JP7735306B2 (ja) | 2020-04-01 | 2025-09-08 | エクシリオ デベロップメント， インコーポレイテッド | マスクされたｉｌ－２サイトカイン及びその切断産物 |
| IL296911A (en) | 2020-04-01 | 2022-12-01 | Xilio Dev Inc | Masked il-15 cytokines and their cleavage products |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| US11597753B2 (en) | 2020-04-30 | 2023-03-07 | Immune Targeting, Inc. | Activatable IL2 composition and methods of use |
| JP2023526428A (ja) | 2020-05-19 | 2023-06-21 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なｉｌ－１２ポリペプチド及びその使用方法 |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| EP4695281A1 (en) * | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
-
2021
- 2021-04-09 AU AU2021254283A patent/AU2021254283B2/en active Active
- 2021-04-09 CA CA3174786A patent/CA3174786A1/en active Pending
- 2021-04-09 BR BR112022020440A patent/BR112022020440A2/pt unknown
- 2021-04-09 MX MX2022012592A patent/MX2022012592A/es unknown
- 2021-04-09 CN CN202180030934.8A patent/CN115667523B/zh active Active
- 2021-04-09 IL IL297225A patent/IL297225A/en unknown
- 2021-04-09 KR KR1020227037537A patent/KR20220167295A/ko active Pending
- 2021-04-09 WO PCT/US2021/026675 patent/WO2021207669A1/en not_active Ceased
- 2021-04-09 EP EP21722711.5A patent/EP4133085A1/en active Pending
- 2021-04-09 JP JP2022561460A patent/JP2023520922A/ja active Pending
- 2021-04-09 US US17/227,017 patent/US11365233B2/en active Active
-
2022
- 2022-05-25 US US17/824,294 patent/US12091442B2/en active Active
-
2024
- 2024-08-15 US US18/806,635 patent/US20250179141A1/en active Pending
-
2026
- 2026-01-12 AU AU2026200173A patent/AU2026200173A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210317177A1 (en) | 2021-10-14 |
| AU2026200173A1 (en) | 2026-02-05 |
| US12091442B2 (en) | 2024-09-17 |
| JP2023520922A (ja) | 2023-05-22 |
| US20250179141A1 (en) | 2025-06-05 |
| AU2021254283B2 (en) | 2025-12-11 |
| CN115667523A (zh) | 2023-01-31 |
| US11365233B2 (en) | 2022-06-21 |
| CA3174786A1 (en) | 2021-10-14 |
| EP4133085A1 (en) | 2023-02-15 |
| AU2021254283A1 (en) | 2022-11-10 |
| CN115667523B (zh) | 2026-03-31 |
| WO2021207669A1 (en) | 2021-10-14 |
| BR112022020440A2 (pt) | 2022-12-27 |
| KR20220167295A (ko) | 2022-12-20 |
| IL297225A (en) | 2022-12-01 |
| US20220402990A1 (en) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012592A (es) | Construcciones de citocinas activables y composiciones y metodos relacionados. | |
| WO2022197764A3 (en) | Masked activatable cytokine constructs and related compositions and methods | |
| MX2024004301A (es) | Construcciones de citocinas activables y metodos combinados. | |
| WO2023060156A3 (en) | Activatable cytokine constructs and related compositions and methods | |
| CN102148563B (zh) | 一种跟踪电源、电源控制方法及通信设备 | |
| CN102142768B (zh) | 一种快速跟踪电源装置、控制方法及通信设备 | |
| US8773205B2 (en) | Doherty power amplifier and implementation method thereof | |
| TW200518535A (en) | High performance modulator architecture for the outphasing rf amplifier | |
| CA2468625A1 (en) | N-way rf power amplifier with increased backoff power and power added efficiency | |
| CN104702224A (zh) | Rf功率放大和分配系统、等离子点火系统及其操作方法 | |
| CN104993796B (zh) | 一种Doherty功率放大器 | |
| CN103166435A (zh) | 一种基于igbt串联损耗优化电压自适应控制方法 | |
| CN101783652A (zh) | 一种易于实现的多级Doherty功放 | |
| US20140035678A1 (en) | Power Amplifier Apparatus and Power Amplifier Circuit | |
| US8773206B2 (en) | Power amplifier apparatus and power amplifier circuit | |
| ZA202307029B (en) | Communication apparatuses and communication methods for operating in a power saving state | |
| WO2022216386A3 (en) | T-type calcium channel antagonists and uses thereof | |
| CN205195668U (zh) | 一种s波段测波雷达功率放大器装置 | |
| CN101662222B (zh) | 电源跟踪方法和装置 | |
| US20130214866A1 (en) | Power amplifier tube and power amplification method | |
| CN201499137U (zh) | 功率放大器 | |
| CN201113924Y (zh) | 带直流偏置的二极管双平衡混频器 | |
| GB672865A (en) | Improvements in and relating to radio ranging systems | |
| CN104836536A (zh) | 一种基于负反馈的功率放大器结构 | |
| WO2023010083A3 (en) | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |